Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Back to dashboard
Company Information
About this company
Key people
Thomas W. Burnell
Executive Chairman, President, Chief Executive Officer
Christopher Mccarthy
Chief Financial Officer
Vijay Aggarwal
Independent Director
Joseph D. Keegan
Independent Director
Fortunato Ron Rocca
Independent Director
Stephen J. Sullivan
Independent Director
Click to see more
Key facts
- Shares in issue5.57m
- EPICIDXGD
- ISINUS46062X4025
- LocationUnited States
- SectorHealthcare
- IndustryHealthcare Facilities
- Market cap$38.67m
- Employees102
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.